Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma.
Department of Pediatrics, Multi-Specialty Tuberous Sclerosis Clinic, Division of Child Neurology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Debopam
D
Samanta
D000287:Administration, Topical; D018322:Angiofibroma / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005153:Facial Neoplasms / Q000188:drug therapy*; D006801:Humans; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases